Madrigal Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic and liver diseases. Co.'s main product candidate, MGL-3196 (resmetirom), is a proprietary, orally administered, small molecule, liver-directed, thyroid hormone receptor-ß selective agonist being developed as a once-daily oral pill that can potentially be used to treat a number of disease states including non-alcoholic steatohepatitis. The MDGL stock yearly return is shown above.
The yearly return on the MDGL stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2015 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the MDGL annual return calculation with any dividends reinvested as applicable (on ex-dates).
|